Book/Share of Coherus BioSciences, Inc.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|NIHD NII Holdings, Inc.||NASDAQ > Public Utilities > Telecommunications Equipment||$474.3M|
|NTRA Natera, Inc.||NASDAQ > Health Care > Medical Specialities||$474.97M|
|WTBA West Bancorporation||NASDAQ > Finance > Major Banks||$475.27M|
|HCCI Heritage-Crystal Clean, Inc.||NASDAQ > Basic Industries > Miscellaneous||$476.82M|
|MNKD MannKind Corporation||NASDAQ > Health Care > Major Pharmaceuticals||$477.87M|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||$478.35M|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||$478.51M|
|HDB HDFC Bank Limited||NYSE > Finance > Commercial Banks||$527.41B|
|MSFT Microsoft Corporation||NASDAQ > Technology > Computer Software: Prepackaged Software||$663.03B|
|GOOG Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.31B|
|GOOGL Alphabet Inc.||NASDAQ > Technology > Computer Software: Programming, Data Processing||$663.8B|
|AMZN Amazon.com, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||$714.48B|
|AAPL Apple Inc.||NASDAQ > Technology > Computer Manufacturing||$920.16B|